

# Shuji Ozaki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7089032/publications.pdf>

Version: 2024-02-01

34  
papers

774  
citations

623734

14  
h-index

501196

28  
g-index

35  
all docs

35  
docs citations

35  
times ranked

738  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells. <i>Biochemical and Biophysical Research Communications</i> , 1999, 258, 583-591.                       | 2.1 | 189       |
| 2  | Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24. <i>Blood</i> , 1997, 90, 3179-3186.  | 1.4 | 75        |
| 3  | HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 967-976.  | 4.2 | 57        |
| 4  | Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells. <i>Blood</i> , 1999, 93, 3922-3930.  | 1.4 | 56        |
| 5  | Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma. <i>International Journal of Hematology</i> , 2007, 86, 180-185.                                     | 1.6 | 50        |
| 6  | Interferon- $\gamma$ enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. <i>Cancer Science</i> , 2008, 99, 2461-2466.                         | 3.9 | 41        |
| 7  | Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. <i>Blood</i> , 2005, 106, 3538-3545.  | 1.4 | 39        |
| 8  | The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. <i>Molecular Immunology</i> , 1999, 36, 387-395.   | 2.2 | 37        |
| 9  | Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. <i>Oncology Reports</i> , 2006, 15, 361-7.   | 2.6 | 30        |
| 10 | JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). <i>International Journal of Hematology</i> , 2019, 109, 509-538.   | 1.6 | 27        |
| 11 | Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma. <i>Cancers</i> , 2020, 12, 12.                   | 3.7 | 25        |
| 12 | A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients. <i>Cancer Science</i> , 2010, 101, 2227-2233.    | 3.9 | 21        |
| 13 | Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. <i>Lung Cancer</i> , 2009, 63, 23-31.  | 2.0 | 17        |
| 14 | Variable-region subgroup distribution among $\Gamma$ -type immunoglobulins in normal human serum. <i>Journal of Clinical Laboratory Analysis</i> , 1994, 8, 4-9.   | 2.1 | 16        |
| 15 | Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors. <i>PLoS ONE</i> , 2013, 8, e83905.                                     | 2.5 | 16        |
| 16 | Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: Correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24. <i>Leukemia Research</i> , 2006, 30, 949-956. | 0.8 | 13        |
| 17 | Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells. <i>BioMed Research International</i> , 2014, 2014, 1-7.   | 1.9 | 12        |
| 18 | Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 1703-1711.  | 1.8 | 11        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24. <i>Cancer</i> , 1998, 82, 2184-2190.  | 4.1 | 9         |
| 20 | Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma. <i>International Journal of Hematology</i> , 2009, 89, 223-226.  | 1.6 | 9         |
| 21 | Thrombopoietin-responsive essential thrombocythaemia with myelofibrosis. <i>British Journal of Haematology</i> , 1997, 97, 449-452.  | 2.5 | 8         |
| 22 | Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma. <i>International Journal of Hematology</i> , 2011, 93, 257-259.  | 1.6 | 4         |
| 23 | Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSC-0902). <i>Annals of Hematology</i> , 2016, 95, 921-929.  | 1.8 | 3         |
| 24 | Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 191-203. | 2.5 | 3         |
| 25 | Biclonal Lymphoplasmacytic Immunocytoma Associated with Crohn's Disease.. <i>Internal Medicine</i> , 1999, 38, 500-503.  | 0.7 | 2         |
| 26 | Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the heavy/light chain assay. <i>Hematological Oncology</i> , 2019, 37, 316-318.  | 1.7 | 1         |
| 27 | Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24. , 1998, 82, 2184.   |     | 1         |
| 28 | SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.. <i>Blood</i> , 2006, 108, 3479-3479.  | 1.4 | 1         |
| 29 | The Serine/Threonine Kinase Pim-2 Is a Novel Anti-Apoptotic Mediator in Myeloma Cells.. <i>Blood</i> , 2007, 110, 243-243.   | 1.4 | 1         |
| 30 | Angiogenesis and Osteoclastogenesis Are Mutually Stimulated in Myeloma: A Role for VEGF and Osteopontin.. <i>Blood</i> , 2005, 106, 2500-2500.   | 1.4 | 0         |
| 31 | Multi-Drug Resistant Leukemic Cells Highly Express HLA Class I Molecules and Single-Chain Fv Diabody Specific to HLA-A Overcomes Drug Resistance in These Cells.. <i>Blood</i> , 2007, 110, 2376-2376.   | 1.4 | 0         |
| 32 | Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL.. <i>Blood</i> , 2007, 110, 244-244.   | 1.4 | 0         |
| 33 | Enzyme-linked immunosorbent assay for variable region .LAMBDA. VI subgroup of light chain in serum: method and results in normal subjects and patients with hyper- and hypogammaglobulinemia.. <i>Japanese Journal of Clinical Immunology</i> , 1994, 17, 172-181.                                       | 0.0 | 0         |
| 34 | Multiple myeloma treatment “ should be continued or not?. <i>British Journal of Haematology</i> , 2022, , .  | 2.5 | 0         |